Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00579527 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Thymus Transplantation With Immunosuppression #950
A Phase 1 study, sponsored by Sumitomo Pharma Switzerland.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00579527 is a Phase 1 study that has completed, run by Sumitomo Pharma Switzerland. The registered enrollment target is 14 participants.
The verdict
NCT00579527, a Phase 1 study, has completed, sponsored by Sumitomo Pharma Switzerland.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also evaluate whether cultured thymus tissue implantation and parathyroid transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly and hypoparathyroidism.
Interventions
- PROCEDURE Blood Draw
- DRUG Cyclosporine
- DRUG Rabbit anti-thymocyte globulin
- BIOLOGICAL Cultured Thymus Tissue for Implantation (CTTI)
- OTHER Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-12-19 |
| Est. Completion | 2017-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00579527
The ClinicalTrials.gov registry entry for NCT00579527 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma Switzerland, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Blood Draw is the first listed.
NCT00579527 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00579527 about?
NCT00579527 is a clinical study titled "Phase I/II Thymus Transplantation With Immunosuppression #950". The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also ...
What is the current status of trial NCT00579527?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2005-12-19. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT00579527?
The interventions under investigation include: Blood Draw (PROCEDURE), Cyclosporine (DRUG), Rabbit anti-thymocyte globulin (DRUG), Cultured Thymus Tissue for Implantation (CTTI) (BIOLOGICAL), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation (OTHER).
Who is sponsoring clinical trial NCT00579527?
This trial is sponsored by Sumitomo Pharma Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.